Gabriela Hobbs/Massachusetts General Hospital
Sep 4, 2025, 18:00
SOHO 2025: Gabriela Hobbs on Emerging Strategies for Managing Polycythemia Vera and Essential Thrombocythemia
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Gabriela Hobbs, Massachusetts General Hospital News
Discusses novel therapies in development for treatment of Polycythemia Vera, including modulators of hepcidin-ferroportin, bomedemstat, givinostat, and novel JAKis, and in Essential Thrombocythemia, including ropeginterferon, bomedemstat, and CALR-directed agents.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation